ADARx Pharmaceuticals, Inc. (ADRX)
12.67
-1.49
(-10.52%)
USD |
NASDAQ |
Nov 20, 16:00
12.67
0.00 (0.00%)
After-Hours: 16:15
ADARx Pharmaceuticals Net Income (Quarterly) : -28.12M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -28.12M |
| June 30, 2026 | -25.76M |
| March 31, 2026 | -22.67M |
| Date | Value |
|---|---|
| June 30, 2025 | -18.09M |
| March 31, 2025 | -15.55M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | -46.42M |
| IRulya Therapeutics, Inc. | -27.74M |
| PepGen Inc. | -19.39M |
| Q32 Bio, Inc. | -8.922M |
| Bridgebio Oncology Therapeutics, Inc. | -34.18M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 2.217M |
| Total Expenses (Quarterly) | 30.33M |
| EPS Diluted (Quarterly) | -0.2749 |
| Enterprise Value | 624.20M |
| Gross Profit Margin (Quarterly) | 66.26% |
| Profit Margin (Quarterly) | -1.27K% |
| Earnings Yield | -7.09% |
| Normalized Earnings Yield | -6.985 |